首页 工具
登录
购物车
Cardioxane

Cardioxane

产品编号 T6467   CAS 149003-01-0
别名: ADR-529 Hydrochloride, ICRF-187 hydrochloride, ADR-529, 右雷佐生盐酸盐, Dexrazoxane HCl, Cardioxane hydrochloride, ICRF-187

Cardioxane (ADR-529) 是一种心脏保护剂。

TargetMol的所有产品和服务仅用于科学研究,不能被用于人体,我们也不向个人提供产品和服务。
Cardioxane Chemical Structure
Cardioxane, CAS 149003-01-0
规格 价格/CNY 货期 数量
5 mg ¥ 257 现货
10 mg ¥ 413 现货
25 mg ¥ 632 现货
50 mg ¥ 813 现货
100 mg ¥ 1,120 现货
200 mg ¥ 1,660 现货
500 mg ¥ 2,790 现货
1 mL * 10 mM (in DMSO) ¥ 293 现货
其他形式的 Cardioxane:
产品目录号及名称: Cardioxane (T6467)
点击图片重新获取验证码
选择批次  
更多批次查询请联系客服
生物活性
化学信息
存储 & 溶解度
参考文献
产品描述 Cardioxane (ADR-529) is a cardio-protective drug.
体外活性 Dexrazoxane (10 mM), known clinically to limit anthracycline cardiac toxicity, prevents daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations in rat cardiac myocytes. [1] Dexrazoxane presumably exerts its cardioprotective effects by either binding free or loosely bound iron, or iron complexed to doxorubicin, thus preventing or reducing site-specific oxygen radical production that damages cellular components. [2] Dexrazoxane specifically abolishes the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes. Dexrazoxane also induces rapid degradation of Top2beta, which paralleles the reduction of doxorubicin-induced DNA damage. Dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity. [3] Dexrazoxane is hydrolyzed to its active form intracellularly and binds iron to prevent the formation of superhydroxide radicals, thus preventing mitochondrial destruction. [4]
体内活性 Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin reduces the tissue lesions in B6D2F1 mice (expressed as area under the curve of wound size times duration) by 96%, 70%, and 87%, respectively. Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin results in a statistically significant reduction in the fraction of mice with wounds as well as the duration of wounds. [5]
激酶实验 HTRF assay: Homogeneous time-resolved fluorescence (HTRF) assay measures the signal generated by 2 components when they are in close proximity. The p53–MDM2 binding assay uses a biotinylated peptide derived from the MDM2-binding domain of p53 and a truncated N-terminal portion of recombinant human GST-tagged MDM2 protein containing the p53-binding domain. Proteins for crystal structure studies are expressed in E. coli strain BL21 using the helper plasmid pUBS 520 coding for the lacIq repressor and the rare tRNAArg [AGA/AGG]. For crystallization, the frozen protein is thawed and concentrated to 9.8 mg/mL using a Centricon concentrator (3,000 MW cutoff). The complex is then formed by combining the protein with a slight molar excess of the inhibitor (stock solution is 100 mM in DMSO) and this solution is allowed to sit for 4 hours at 4°C. Cryopreserved crystals are used to collect diffraction data on beamline X8C at the National Synchrotron Light Source at Brookhaven National Laboratory.
别名 ADR-529 Hydrochloride, ICRF-187 hydrochloride, ADR-529, 右雷佐生盐酸盐, Dexrazoxane HCl, Cardioxane hydrochloride, ICRF-187
分子量 304.73
分子式 C11H16N4O4·HCl
CAS No. 149003-01-0

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

H2O: 55 mg/mL (180.5 mM)

DMSO: 56 mg/mL (183.8 mM)

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

溶液配制表

可选溶剂 浓度 体积 质量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.2816 mL 16.408 mL 32.8159 mL 82.0398 mL
5 mM 0.6563 mL 3.2816 mL 6.5632 mL 16.408 mL
10 mM 0.3282 mL 1.6408 mL 3.2816 mL 8.204 mL
20 mM 0.1641 mL 0.8204 mL 1.6408 mL 4.102 mL
50 mM 0.0656 mL 0.3282 mL 0.6563 mL 1.6408 mL
100 mM 0.0328 mL 0.1641 mL 0.3282 mL 0.8204 mL

计算器

摩尔浓度计算器
稀释计算器
配液计算器
分子量计算器
=
X
X
X
=
X
=
/
g/mol

输入分子式,点击计算,可计算出产品的分子量。

参考文献

1. Sawyer DB, et al. Circ Res, 1999, 84(3), 257-265. 2. Hasinoff BB, et al. Curr Med Chem, 1998, 5(1), 1-28. 3. Lyu YL, et al. Cancer Res, 2007, 67(18), 8839-8846. 4. Seifert CF, et al. Ann Pharmacother, 1994, 28(9), 1063-1072. 5. Langer SW, et al. Clin Cancer Res, 2000, 6(9), 3680-3686. 6. Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. Journal of chemical information and modeling. 2019, 59(10): 4374-4382.

文献引用

1. Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation. Journal of chemical information and modeling. 2019, 59(10): 4374-4382.
Pirarubicin Topotecan hydrochloride Ciprofloxacin monohydrochloride EIDD-1931 Sophoridine SW044248 Isodiospyrin Gimatecan HCl

相关化合物库

该产品包含在如下化合物库中:
抗心血管疾病化合物库 药物功能重定位化合物库 抗衰老化合物库 表型筛选靶点鉴定库 铁死亡化合物库 儿童药物库 FDA上市及药典收录分子库 临床期小分子药物库 经典已知活性库 临床前化合物库

剂量换算

对于不同动物的给药剂量换算,您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。

第一步:请输入动物实验的基本信息
剂量
mg/kg
每只动物体重
g
给药体积
μL
动物数量
第二步:请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
% Tween 80
% ddH2O
计算 重置

技术支持

您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。

Keywords

Cardioxane 149003-01-0 DNA Damage/DNA Repair Topoisomerase Dexrazoxane ICRF 187 ADR-529 Hydrochloride inhibit ICRF-187 hydrochloride Cardioxane Hydrochloride ADR-529 Inhibitor NSC-169780 Dexrazoxane hydrochloride ADR 529 右雷佐生盐酸盐 ICRF187 ADR 529 Hydrochloride NSC 169780 Dexrazoxane HCl ICRF 187 Hydrochloride NSC169780 Cardioxane hydrochloride ADR529 Hydrochloride ADR529 ICRF187 Hydrochloride ICRF-187 Hydrochloride ICRF-187 inhibitor

 

陶术
生物
TargetMol®中国区唯一合作伙伴
点击进入陶术生物官网陶术生物
联系我们
400-820-0310

上海市静安区江场三路238号8楼